Table 3. Prevalence of low hormone and high SHBG concentration by age, 1,351 male participants, NHANES III, 1988-1991.

Age group (years)	Prevalence		Population size^**
Age group (years)	%	95% CI	population	95% CI
Total testosterone (<10.41 nmol/L)
20-29	2.3	^*	450,313	^*
30-39	4.8	(1.8 -7.8)	938,276	(330,431 -1,546,121)
40-49	8.7	(4.1 -13.2)	1,901,808	(898,901 -2,904,716)
50-59	12.8	(7.4 -18.3)	2,316,136	(1,328,953 -3,303,319)
60-69	15	(7.4 -22.6)	1,645,256	(813,351 -2,477,160)
70+	24.9	(16.3 -33.5)	2,581,414	(1,689,385 -3,473,443)
40+			8,444,613	(4,730,590 -12,158,637)
Free testosterone (<0.173 nmol/L)
20-29	0	^*	0	^*
30-39	1.3	^*	264,693	^*
40-49	4.5	(1.0 -7.9)	977,257	(211,088 -1,743,427)
50-59	6.8	(0.9 -12.7)	1,227,570	(162,545 -2,292,595)
60-69	7.6	(3.8 -11.4)	829,191	(413,239 -1,245,143)
70+	30.2	(22.2 -38.2)	3,125,688	(2,296,650 -3,954,726)
40+			6,159,706	(3,083,521 -9,235,892)
Total estradiol (<73.42 pmol/L)
20-29	0.3	^*	54,038	^*
30-39	3.4	^*	669,633	^*
40-49	4.2	^*	922,355	^*
50-59	0.9	^*	153,446	^*
60-69	5.1	(0.8 -9.5)	561,181	(87,339 -1,035,023)
70+	8.3	(2.2 -14.4)	860,471	(230,565 -1,490,378)
40+			2,497,454	^*
Free estradiol (<2.17 pmol/L)
20-29	4.8	^*	960,667	^*
30-39	8.1	(3.0 -13.2)	1,600,008	(601,129 -2,598,887)
40-49	5.8	(1.2 -10.3)	1,262,748	(272,754 -2,252,742)
50-59	5.3	(1.7 -8.8)	951,367	(307,398 -1,595,336)
60-69	12.2	(5.0 -19.4)	1,335,676	(544,510 -2,126,843)
70+	23.9	(18.8 -28.9)	2,472,559	(1,952,378 -2,992,740)
40+			6.022.350	(3.077.039 -8.967.661)
SHBG (>66 nmol/L)
20-29	0.4	^*	72,050	^*
30-39	2	(0.4 -3.5)	385,187	(71,586 -698,789)
40-49	6.2	(3.2 -9.2)	1,354,984	(696,422 -2,013,545)
50-59	9.6	(3.9 -15.4)	1,740,261	(703,542 -2,776,980)
60-69	8.8	(5.1 -12.4)	961,556	(562,756 -1,360,355)
70+	32.1	(23.4 -40.7)	3,325,773	(2,429,681 -4,221,866)
40+			7,382,573	(4,392,401 -10,372,746)

95% CIs were not estimated because relative standard error is >30% and, thus, unreliable

^**

Projected population size between the 2000 and 2010 US Censuses.